Faculty Disclosure

V. Craig Jordan, OBE, PhD, DSc
Reshma Jagsi, MD, PhD
City of Hope
Arti Hurria, MD
Massachusetts General Cancer Center of Northwestern University
Kevin Hughes, MD
Northwestern University
Cancer Center of Robert H. Lurie Comprehensive Hospital
Nora Hansen, MD
Northwestern University Cancer Center of Robert H. Lurie Comprehensive
William Gradishar, MD
Northwestern University Cancer Center of Robert H. Lurie Comprehensive
Jose Baselga, MD, PhD
University of Washington
Benjamin Anderson, MD
Cancer Center of Robert H. Lurie Comprehensive
Cancer Center
Baylor Sammans US Oncology/Texas Oncology & Texas Oncology
Ruth O’Regan, MD
Cancer Center University of North Carolina
Hyman Muss, MD
Cancer Center MD Anderson Cancer Center
Monica Morrow, MD
MD Anderson Cancer Center The University of Texas
Mark Robson, MD
Harvard Medical School Medical Center/Beth Israel Deaconess
Mater Misericordiae Malcolm Kell, MD
Memorial Sloan Kettering Cancer Center
Tari King, MD
Northwestern University Cancer Center of Robert H. Lurie Comprehensive
Robert H. Lurie Comprehensive Seema Khan, MD
Kalliopi Siziopikou, MD, PhD
Cancer Center Cancer Center
Mater Misericordiae Lajos Pusztai, MD
Yale University
Lynn Sage Breast Cancer Symposium
19TH ANNUAL LYNN SAGE BREAST CANCER SYMPOSIUM SEPTEMBER 14-17, 2017 Chicago Marriott Downtown Magnificent Mile SYMPOSIUM CHAIR
William Gradishar, MD SYMPOSIUM CO-CHAIRS
Monica Morrow, MD; V Craig Jagsi, MD, PhD, DSc
Nora Hansen, MD

Reflected in the most valuable breast cancer meeting worldwide for the practicing clinician, the Lynn Sage Breast Cancer Symposium provides 3.5 days of formal presentations and interactive case discussions. For 19 years, this multidisciplinary CME program has been bringing together leading national and international medical, surgical, and radiation oncologists to present, debate, and evaluate cutting-edge technology and approaches in the management of breast cancer. Progress across all aspects of patient care, including prevention, screening, detection, and survivorship, as well as in the primary treatment modalities of surgery, radiation therapy, endocrine therapy, cytotoxic chemotherapy, and novel biologic therapies are leading to new strategies and therapeutic options. The symposium focuses on the close cooperative model for effective multidisciplinary management of patients with breast cancer.

Educational Objectives

1. Practice current management approaches for high-risk breast cancer.
2. Describe factors influencing the choice of initial therapeutic approaches—neoadjuvant chemotherapy, mastectomy or oncoplastic breast conservation in operable breast cancer.
3. Identify the multidisciplinary challenges and opportunities associated with the use of neoadjuvant chemotherapy in operable breast cancer.
5. Employ optimal strategies for overcoming endocrine resistance by incorporating targeted therapies.
6. Cite the clinical and molecular factors that determine the optimal duration of adjuvant endocrine therapy.
7. Utilize optimal surgical and medical strategies in the elderly with breast cancer.

Register by July 31, 2017 for early bird discount.